Edwards Lifesciences Corporation (BVMF:E1WL34)

Market Cap	263.23B
Revenue (ttm)	31.36B
Net Income (ttm)	7.29B
Shares Out	n/a
EPS (ttm)	12.42
PE Ratio	36.11
Forward PE	30.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	71
Open	113.82
Previous Close	116.16
Day's Range	113.82 - 113.82
52-Week Range	98.15 - 120.94
Beta	0.96
RSI	44.27
Earnings Date	Feb 13, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: E1WL34

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Financial numbers in USD